Brief ReportA Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
Keywords
Cited by (0)
Disclosure: Dr. Ikeda reports receiving grants and personal fees from Chugai Pharmaceuticals, during the conduct of the study; grants and personal fees from AstraZeneca; and personal fees from Boehringer Ingelheim, Ono Pharmaceuticals, Taiho Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly, outside of the submitted work. Dr. Kato reports receiving grants and personal fees from Chugai Pharmaceuticals, during the conduct of the study; grants and personal fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Biopharma, Merck Sharp & Dohme, Novartis, Ono Pharmaceuticals, Pfizer, and Taiho Pharmaceuticals; personal fees from Daiichi Sankyo, F. Hoffmann-La Roche, Nippon Kayaku, Nitto Denko, Shionogi, Sumitomo Dainippon, and Takeda Pharmaceuticals; and grants from Astellas, Kyorin, Kyowa Kirin, and Regeneron, outside of the submitted work. Dr. Kenmotsu reports receiving grants and personal fees from Chugai Pharmaceuticals, during the conduct of the study; grants and personal fees from AstraZeneca and Novartis; and personal fees from Ono Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Kyowa Hakko Kirin, Bristol-Myers Squibb, Merck Sharp & Dohme, Daiichi Sankyo, and Pfizer, outside of the submitted work. Dr. Ogura reports receiving personal fees from Shionogi, Nippon Boehringer Ingelheim, and Eisai, outside of the submitted work. Dr. S. Iwasawa reports receiving personal fees from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme, and Chugai Pharmaceuticals; and grants and personal fees from Ono Pharmaceuticals, outside of the submitted work. Dr. Sato reports receiving personal fees from Ono Pharmaceuticals, Novartis, Taiho Pharmaceuticals, and Chugai Pharmaceuticals, outside of the submitted work. Harada reports receiving personal fees from Chugai Pharmaceuticals, outside of the submitted work. Dr. Kubota reports receiving grants and personal fees from Taiho Pharmaceuticals; grants from Boehringer Ingelheim and Ono Pharmaceuticals; and personal fees from Merck Sharp & Dohme and Chugai Pharmaceuticals, outside of the submitted work. Dr. Tokito reports receiving personal fees from AstraZeneca, Merck Sharp & Dohme, Boehringer Ingelheim, and Chugai Pharmaceuticals, outside of the submitted work. Dr. I. Okamoto reports receiving grants and personal fees from AstraZeneca, Taiho Pharmaceuticals, Boehringer Ingelheim, Ono Pharmaceuticals, Merck Sharp & Dohme, Eli Lilly, Bristol-Myers Squibb, and Chugai Pharmaceuticals; grants from Astellas, Novartis, and AbbVie; and personal fees from Pfizer, outside of the submitted work. Dr. Furuya reports receiving personal fees from Eli Lilly, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim Japan, Taiho Pharmaceuticals, Ono Pharmaceuticals, Pfizer Japan, and Chugai Pharmaceuticals, outside of the submitted work. Dr. Yokoyama reports receiving personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Ono Pharmaceuticals, Taiho Pharmaceuticals, Merck Sharp & Dohme, Pfizer, Novartis, and Chugai Pharmaceuticals, outside of the submitted work. Dr. T. Iwasawa reports receiving personal fees from Ono Pharmaceuticals and Boehringer Ingelheim and grants from Canon Medical Systems, outside of the submitted work. Dr. Yamanaka reports receiving grants and personal fees from Takeda Pharmaceuticals, Chugai Pharmaceuticals, Boehringer Ingelheim, Taiho Pharmaceuticals, Daiichi Sankyo, and Bayer; grants from Ono Pharmaceuticals, Merck, Astellas, and Eli Lilly; and personal fees from Pfizer, Sysmex, Huya Biosciences, and Gilead Sciences, outside of the submitted work. Dr. H. Okamoto reports receiving grants from AMED, Takeda Pharmaceuticals, Merck, and Daiich Sankyo; grants and personal fees from Merck Sharp & Dohme, Ono Pharmaceuticals, AstraZeneca, Chugai Pharmaceuticals, Taiho Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly; and personal fees from Kyorin, Boehringer Ingelheim, and Novartis, outside of the submitted work. Dr. Hosokawa declares no conflict of interest.